AndrewSaulArtzMDMS

Oncology • Duarte, CA

Hematologic Oncology

Professor of Hematology and Hematopoietic Cell Transplantation City of Hope

Join to view full profile

Dr. Artz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Artz's full profile

Already have an account?

Office
1500 Duarte Rd
Duarte, CA 91010
Phone+1 626-256-4673

Fax+1 626-408-3911

Summary

Dr. Andrew Artz is a hematologist/oncologist affiliated with City of Hope Medical Center in Duarte, CA. He received his medical degree from West Virginia University School of Medicine, medicine training at Georgetown University, and Hematology/Oncology fellowship at the University of Chicago. He specializes in treating blood cancers through the use of stem cell transplantation. Dr. Artz is the Director of the Program for Aging and Blood Cancers at City of Hope.

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2001 - 2004
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1997 - 2000
West Virginia University School of MedicineClass of 1997

Certifications & Licensure

IL State Medical License 2000 - 2026
CA State Medical License 2019 - 2025
DC State Medical License 1999 - 2002
VA State Medical License 1998 - 2002
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies Start of enrollment: 2001 Nov 01
Completed
Phase 2
Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes Start of enrollment: 2008 Oct 02
Active, not recruiting
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies Start of enrollment: 2003 May 01
Terminated
Phase 1
Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies Start of enrollment: 2012 Mar 01
Completed
Phase 1, Phase 2
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies Start of enrollment: 2006 Mar 01
Completed
Phase 1, Phase 2
Combined Haploidentical-Cord Blood Transplantation for Adults and Children Start of enrollment: 2006 Oct 09
Completed
Not Applicable
Stem Cell Related Donor Safety Study Start of enrollment: 2010 Jan 01
Completed
Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia Start of enrollment: 2008 Dec 01
Withdrawn
Not Applicable
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Trial To Evaluate the Efficacy of Intravenous Iron in Older Adults With Unexplained Anemia Start of enrollment: 2011 May 01
Terminated
Phase 2
Cord Blood Transplantation for Patients With Cancer Start of enrollment: 2010 Apr 01
Terminated
Phase 2
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102) Start of enrollment: 2013 Dec 16
Completed
Phase 2
The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients Start of enrollment: 2016 Feb 04
Terminated
Phase 2
Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704) Start of enrollment: 2019 Jul 19
Completed
Join now to see all

Publications & Presentations

PubMed

198 citations
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
Lori Muffly, Marcelo C. Pasquini, Michael Martens, Ruta Brazauskas, Xiaochun Zhu
Blood. 2017-08-31
45 citations
Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes.
Rebecca L. Olin, Caitrin Fretham, Marcelo C. Pasquini, Mukta Arora, Vijaya Raj Bhatt
Blood Advances. 2020-06-23
201 citations
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Pa...
Robert J. Soiffer, Haesook T. Kim, Joseph P. McGuirk, Mitchell E. Horwitz, Laura Johnston
Journal of Clinical Oncology. 2017-10-17

Abstracts/Posters

Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A...
Andrew S. Artz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors
Andrew S. Artz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS
Andrew S. Artz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Resul...
Andrew S. Artz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Adult and Pediatric BMT
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: A Systematic Review with a Specific Focus o...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Hematology & Aging: Scientific Advances From Sickle Cell Disease to Malignant Hematology
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

City of Hope Researchers Present Innovative Studies at American Society of Hematology (ASH) Annual MeetingDecember 13th, 2022
City of Hope Doctors Present New Research on Cancer ImmunotherapiesNovember 4th, 2021
Sydnexis Raises $45M in Series B FundingAugust 11th, 2021
Join now to see all